ArticleMolecular and clinical oncology2026
A cascade via CD276/PI3K/SIRT1/E-Cad in overcoming contact inhibition of proliferation in hepatocellular carcinoma cells.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PVR Mediates Resistance to IL21.CD276.CAR-T Therapy in Esophageal Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contact inhibition of proliferation (CIP) halts normal cell proliferation upon confluence, a mechanism often lost in cancer cells, leading to disorganized proliferation. CD276, frequently overexpressed in cancers, promotes proliferation by activating the PI3K/AKT pathway; however, its role in CIP is unexplored. Human HCC cell lines and an immortalized human hepatocyte cell line were cultured under sparse or confluent conditions. Small interfering RNA was transfected to knockdown CD276 expression and plasmid DNA was transfected to overexpress CD276. The cell cycle was analyzed by flow cytometry. Western blotting was used to detect the expression of CD276, E-Cad, SIRT1 and cell cycle proteins. Analysis revealed higher CD276 levels in HCC lines than in HepLi5, with increased CD276 correlating with reduced CIP severity and lower E-Cad expression. Overexpression of CD276 alleviated G0/G1 phase arrest induced by high-density contact, while CD276 knockdown enhanced it. CD276 emerged as a critical regulator of E-Cad in confluent HCC cells through modulating SIRT1 protein via the PI3K/AKT pathway. The findings of the present study highlighted CD276's pivotal role in regulating the cell cycle under confluent culture conditions, revealing a novel regulatory cascade involving CD276/PI3K/SIRT1/E-Cad that may influence tumor progression. This insight into CD276's undisclosed function provides potential treatment strategies for HCC intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.